众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002317 众生药业

已收盘 05-08 15:00:00

{"stockData":{"symbol":"002317","market":"SZ","secType":"STK","nameCN":"众生药业","latestPrice":15.15,"timestamp":1715151786000,"preClose":15.43,"halted":0,"volume":17937192,"delay":0,"floatShares":762000000,"shares":852999999,"eps":0.2053,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.28,"latestTime":"05-08 15:00:00","open":15.44,"high":15.55,"low":15.08,"amount":273000000,"amplitude":0.0305,"askPrice":15.16,"askSize":10,"bidPrice":15.15,"bidSize":38,"shortable":0,"etf":0,"ttmEps":0.2053,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715218200000},"adr":0,"adjPreClose":15.43,"symbolType":"stock","openAndCloseTimeList":[[1715131800000,1715139000000],[1715144400000,1715151600000]],"highLimit":16.97,"lowLimit":13.89,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":853350477,"pbRate":2.99,"roa":"--","roe":"1.17%","epsLYR":0.32,"committee":0.485463,"marketValue":12928000000,"floatMarketCap":11541000000,"peRate":73.794446,"changeRate":-0.0181,"turnoverRate":0.0235,"status":1},"requestUrl":"/m/hq/s/002317/tweets","defaultTab":"tweets","newsList":[{"id":"2433473769","title":"众生药业：4月30日高管陈永红增持股份合计4000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433473769","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433473769?lang=zh_cn&edition=full","pubTime":"2024-05-06 21:01","pubTimestamp":1715000468,"startTime":"0","endTime":"0","summary":"证券之星消息，根据5月6日市场公开信息、上市公司公告及交易所披露数据整理，众生药业最新董监高及相关人员股份变动情况：2024年4月30日公司董事,高管陈永红共增持公司股份4000.0股，占公司总股本为0.0005%。众生药业近半年内的董监高及核心技术人员增减持详情如下：众生药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入1576.76万，融资余额增加；融券净流入10.43万，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600026380.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431857169","title":"众生药业：4月26日高管陈永红增持股份合计4.28万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431857169","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431857169?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:01","pubTimestamp":1714395674,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月29日市场公开信息、上市公司公告及交易所披露数据整理，众生药业最新董监高及相关人员股份变动情况：2024年4月26日公司董事,高管陈永红共增持公司股份4.28万股，占公司总股本为0.005%。众生药业近半年内的董监高及核心技术人员增减持详情如下：众生药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出151.66万，融资余额减少；融券净流入3.58万，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900030914.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430274019","title":"众生药业：4月25日高管陈永红增持股份合计3.56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430274019","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430274019?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:03","pubTimestamp":1714136637,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月26日市场公开信息、上市公司公告及交易所披露数据整理，众生药业最新董监高及相关人员股份变动情况：2024年4月25日公司董事,高管陈永红共增持公司股份3.56万股，占公司总股本为0.0042%。众生药业近半年内的董监高及核心技术人员增减持详情如下：众生药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入910.94万，融资余额增加；融券净流入3.04万，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600053438.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430838372","title":"众生药业：4月24日高管陈永红增持股份合计2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430838372","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430838372?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:01","pubTimestamp":1714050076,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月25日市场公开信息、上市公司公告及交易所披露数据整理，众生药业最新董监高及相关人员股份变动情况：2024年4月24日公司董事,高管陈永红共增持公司股份2.0万股，占公司总股本为0.0023%。众生药业近半年内的董监高及核心技术人员增减持详情如下：众生药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出832.42万，融资余额减少；融券净流入2.77万，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500044202.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429744439","title":"众生药业：主要是报告期内确认预计退货所致","url":"https://stock-news.laohu8.com/highlight/detail?id=2429744439","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429744439?lang=zh_cn&edition=full","pubTime":"2024-04-24 19:01","pubTimestamp":1713956497,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)04月24日在投资者关系平台上答复投资者关心的问题。投资者：公司公布的年报当中，众生睿创营业收入5700多万，但是在你半年报时，公司公布的众生睿创的营收是7500多万，怎么回事？众生药业董秘：您好！主要是报告期内确认预计退货所致。谢谢！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400039247.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429165917","title":"众生药业(002317)3月31日股东户数9.4万户，较上期减少11.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429165917","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429165917?lang=zh_cn&edition=full","pubTime":"2024-04-23 17:07","pubTimestamp":1713863244,"startTime":"0","endTime":"0","summary":"证券之星消息，近日众生药业披露，截至2024年3月31日公司股东户数为9.4万户，较12月31日减少1.25万户，减幅为11.72%。在中药行业个股中，众生药业股东户数高于行业平均水平，截至3月31日，中药行业平均股东户数为5.19万户。从股价来看，2023年12月31日至2024年3月31日，众生药业区间跌幅为0.5%，在此期间股东户数减少1.25万户，减幅为11.72%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300032961.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429686972","title":"图解众生药业一季报：第一季度单季净利润同比减63.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429686972","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429686972?lang=zh_cn&edition=full","pubTime":"2024-04-23 01:48","pubTimestamp":1713808127,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业2024年一季报显示，公司主营收入6.41亿元，同比下降14.15%；归母净利润5129.39万元，同比下降63.2%；扣非净利润7222.69万元，同比下降43.58%；负债率26.46%，投资收益716.81万元，财务费用223.02万元，毛利率56.49%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300002250.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429152971","title":"图解众生药业年报：第四季度单季净利润同比减122.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429152971","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429152971?lang=zh_cn&edition=full","pubTime":"2024-04-23 00:41","pubTimestamp":1713804115,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业2023年年报显示，公司主营收入26.11亿元，同比下降2.45%；归母净利润2.63亿元，同比下降18.25%；扣非净利润3.05亿元，同比上升1.45%；其中2023年第四季度，公司单季度主营收入5.39亿元，同比下降21.27%；单季度归母净利润-1622.25万元，同比下降122.13%；单季度扣非净利润470.91万元，同比下降85.85%；负债率29.93%，投资收益2352.85万元，财务费用1678.42万元，毛利率58.6%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300000664.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429092406","title":"众生药业最新公告：一季度净利润5129.39万元 同比下降63.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429092406","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429092406?lang=zh_cn&edition=full","pubTime":"2024-04-22 22:00","pubTimestamp":1713794425,"startTime":"0","endTime":"0","summary":"众生药业公布2024年一季度报告，报告期营业收入6.41亿元，同比下降14.15%；归属于上市公司股东的净利润5129.39万元，同比下降63.20%。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200030019.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429924362","title":"众生药业(002317.SZ)发布2023年度业绩，净利润2.63亿元，同比下降18.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429924362","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429924362?lang=zh_cn&edition=full","pubTime":"2024-04-22 21:51","pubTimestamp":1713793914,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)披露2023年年度报告，公司2023年度实现营收26.11亿元，同比下降2.45%;归母净利润2.63亿元，同比下降18.25%;扣非净利润3.05亿元，同比增长1.45%;基本每股收益0.32元。公司拟每10股派发现金红利2元(含税)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107093.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429210629","title":"众生药业(002317.SZ)发布一季度业绩，净利润5129万元，同比下降63.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429210629","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429210629?lang=zh_cn&edition=full","pubTime":"2024-04-22 21:49","pubTimestamp":1713793746,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)披露2024年第一季度报告，报告期公司实现营收6.41亿元，同比下降14.15%;归母净利润5129万元，同比下降63.2%;扣非净利润7223万元，同比下降43.58%。基本每股收益0.06元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107089.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417826129","title":"减肥药没有尽头？","url":"https://stock-news.laohu8.com/highlight/detail?id=2417826129","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2417826129?lang=zh_cn&edition=full","pubTime":"2024-03-06 19:47","pubTimestamp":1709725651,"startTime":"0","endTime":"0","summary":"还能找到上车机会吗?","market":"sg","thumbnail":"https://img3.gelonghui.com/77c2b-61ab3bd5-61a7-4f3b-a2d5-7b03706d81bd.jpg?guru_height=853&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/77c2b-61ab3bd5-61a7-4f3b-a2d5-7b03706d81bd.jpg?guru_height=853&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/702707","is_publish_highlight":false,"gpt_icon":0},{"id":"2415540535","title":"“减肥药”II期临床试验搅动市场，众生药业定增股解禁先抑后扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2415540535","media":"21世纪经济报道","top":-1,"share":"https://www.laohu8.com/m/news/2415540535?lang=zh_cn&edition=full","pubTime":"2024-02-29 21:23","pubTimestamp":1709212980,"startTime":"0","endTime":"0","summary":"近日，该在研产品的两项II期临床试验先后完成首例受试者入组。公告显示，众生药业本次限售股份上市流通日为2024年1月5日，解除限售股份数量为3896.94万股，占众生药业总股本的4.57%，涉及股东共计12名。至此，众生药业定增解禁股东出现了30.99%的账面浮亏。但随着减肥药临床试验进展的持续披露，众生药业股价开始逆转。上述众生药业相关人员表示。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-02-29/doc-inaktmyz1128591.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-02-29/doc-inaktmyz1128591.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2414693333","title":"A股午评：三大指数跳水转跌，半日成交8888亿元！人造肉、减肥药板块走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2414693333","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2414693333?lang=zh_cn&edition=full","pubTime":"2024-02-28 11:39","pubTimestamp":1709091580,"startTime":"0","endTime":"0","summary":"A股主要指数临近午盘休市跳水，4500股下跌，半日成交8888亿元较昨日放量3611亿元；人造肉、减肥药板块走高，机器人、微盘股震荡走低","market":"hk","thumbnail":"https://img3.gelonghui.com/20b77-f0f73b20-83f0-41f3-b6ef-3c433eea8e16.png","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/20b77-f0f73b20-83f0-41f3-b6ef-3c433eea8e16.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/698030","is_publish_highlight":false,"gpt_icon":0},{"id":"2414482781","title":"众生药业(002317.SZ)：RAY1225注射液用于2型糖尿病患者的II期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2414482781","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2414482781?lang=zh_cn&edition=full","pubTime":"2024-02-27 18:50","pubTimestamp":1709031000,"startTime":"0","endTime":"0","summary":"众生药业(002317.SZ)发布公告，公司控股子公司广东众生睿创生物科技有限公司(“众生睿创”)自主研发的一类创新多肽药物RAY1225注射液，已于2024年2月同步启动用于2型糖尿病及超重/肥胖患者的两项II期临床试验，并于近日完成2型糖尿病II期临床试验的首例受试者入组。据悉，RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，属于长效GLP-1类药物，具有GLP-1受体和GIP受体双重激动活性。临床上拟用于2型糖尿病及超重/肥胖等患者的治疗。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-27/doc-inaknpfm7940630.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-27/doc-inaknpfm7940630.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2414824186","title":"众生药业公告，控股子公司一类创新药RAY","url":"https://stock-news.laohu8.com/highlight/detail?id=2414824186","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2414824186?lang=zh_cn&edition=full","pubTime":"2024-02-27 18:05","pubTimestamp":1709028300,"startTime":"0","endTime":"0","summary":"众生药业公告，控股子公司一类创新药RAY1225注射液用于2型糖尿病患者的II期临床试验完成首例受试者入组。               \n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-02-27/doc-inaknpfi3369332.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-02-27/doc-inaknpfi3369332.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2413449432","title":"众生药业：控股子公司一类创新药RAY12","url":"https://stock-news.laohu8.com/highlight/detail?id=2413449432","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2413449432?lang=zh_cn&edition=full","pubTime":"2024-02-21 19:09","pubTimestamp":1708513740,"startTime":"0","endTime":"0","summary":"众生药业：控股子公司一类创新药RAY1225注射液用于超重/肥胖患者的II期临床试验完成首例受试者入组。               \n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-02-21/doc-inaiuyrc0326270.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-02-21/doc-inaiuyrc0326270.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2404380928","title":"众生药业(002317.SZ)子公司米拉贝隆化学原料药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2404380928","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2404380928?lang=zh_cn&edition=full","pubTime":"2024-01-17 18:11","pubTimestamp":1705486260,"startTime":"0","endTime":"0","summary":"众生药业发布公告，公司全资子公司广东先强药业有限公司于近日收到国家药品监督管理局核准签发的原料药米拉贝隆《化学原料药上市申请批准通知书》。本次米拉贝隆原料药获得《化学原料药上市申请批准通知书》，表明该原料药已符合国家相关药品审评技术标准，已批准可在国内制剂中使用和销售，将丰富公司特色原料药产品管线，有利于公司拓展该品种的研发及销售。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-17/doc-inacvtsa2734807.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-17/doc-inacvtsa2734807.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2391511915","title":"众生药业(002317.SZ)：来瑞特韦片等产品入选国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2391511915","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2391511915?lang=zh_cn&edition=full","pubTime":"2023-12-13 18:47","pubTimestamp":1702464420,"startTime":"0","endTime":"0","summary":"公司及子公司共有135个产品品规入选医保目录，其中甲类67个，乙类68个。公司核心产品复方血栓通胶囊、脑栓通胶囊、硫糖铝口服混悬液、羧甲司坦口服溶液、盐酸氮斯汀滴眼液等继续入选本次医保目录。来瑞特韦片为公司抗病毒类的重要产品，本次成功纳入医保目录乙类范围，有望惠及更多患者，为患者提供经济、安全、可及的用药选择。公司及子公司的产品继续入选及新增入选医保目录，将有利于产品的市场推广及未来销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-13/doc-imzxwnsq9612766.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-13/doc-imzxwnsq9612766.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2389433047","title":"众生药业(002317.SZ)董事长陈永红拟增持不低20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2389433047","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2389433047?lang=zh_cn&edition=full","pubTime":"2023-12-07 19:19","pubTimestamp":1701947940,"startTime":"0","endTime":"0","summary":"众生药业(002317.SZ)公告，公司于近日收到《关于计划增持公司股份的通知》，公司董事长、总裁陈永红计划自2023年12月8日起6个月内以自有资金通过集中竞价交易方式增持公司股份，合计增持股份数不低于20万股(含)。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-07/doc-imzxeyav1675249.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-07/doc-imzxeyav1675249.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-12-11","address":"广东省东莞市石龙镇西湖工业区信息产业园","stockEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.009},{"period":"3month","weight":0.2773},{"period":"6month","weight":-0.1091},{"period":"1year","weight":-0.1182},{"period":"ytd","weight":-0.0386}],"companyName":"广东众生药业股份有限公司","boardCode":"AI0027","perCapita":"8102股","boardName":"医药制造业","registeredCapital":"85335万元","compareEarnings":[{"period":"1week","weight":0.0138},{"period":"1month","weight":0.0256},{"period":"3month","weight":0.1124},{"period":"6month","weight":0.0309},{"period":"1year","weight":-0.0728},{"period":"ytd","weight":0.0581}],"survey":"　　广东众生药业股份有限公司主营业务是药品研发、生产、销售。公司主要产品有复方血栓通系列产品、众生丸系列产品、头孢克肟分散片、头孢拉定胶囊、硫糖铝口服混悬液。公司为高新技术企业。公司入选“2022中国医药创新企业100强”、“2021年度中国医药工业百强”、“2022年广东省制造业企业500强”。","serverTime":1715183930778,"listedPrice":55,"stockholders":"94019人(较上一季度减少11.72%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"众生药业,002317,众生药业股票,众生药业股票老虎,众生药业股票老虎国际,众生药业行情,众生药业股票行情,众生药业股价,众生药业股市,众生药业股票价格,众生药业股票交易,众生药业股票购买,众生药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}